Greenwich LifeSciences, Inc.

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) is a public biopharmaceutical company based in the Houston, TX area that is developing GP2, a novel peptide immunotherapy, and has commenced a Phase III clinical trial, called Flamingo-01. GP2 is derived from the HER2/neu protein, which is expressed in a variety of common cancers, including breast cancer. Tumors with elevated expression of HER2/neu protein are highly aggressive, resulting in an increased disease recurrence and a worse prognosis. In a Phase IIb clinical trial in the HER2/neu positive adjuvant setting, no breast cancer recurrences were observed after median 5 years of follow-up if the patient was treated, followed, and remained disease free over the first 6 months, which is the time required to reach peak immunity and thus maximum efficacy and protection (p = 0.0338).